Deregulated expression of TANK in glioblastomas triggers pro-tumorigenic ERK1/2 and AKT signaling pathways

Oncogenesis

Volumn 2, Issue , 2015, Pages

  Stellzig, J ^a   Chariot, A ^b,c   Shostak, K ^b   Ismail Goktuna S ^b   Renner, F ^a,e   Acker, T ^a   Pagenstecher, A ^d   Schmitz, M L ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

ERK; glioblastoma; inflammation; NF kB; TANK; TBK1

Indexed keywords

ADAPTOR PROTEIN; I KAPPA B KINASE; I KAPPA B KINASE EPSILON; INTERFERON REGULATORY FACTOR 3; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SHORT HAIRPIN RNA; TBK1 PROTEIN; TRAF ASSOCIATED NUCLEAR FACTOR KAPPA B ACTIVATOR; UNCLASSIFIED DRUG; VINBLASTINE;

ARTICLE; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE OVEREXPRESSION; GENE SILENCING; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STOICHIOMETRY;

EID: 84908011229     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2013.42     Document Type: Article

References (55)

1. Bailey P, Cushing H. A Classification of the Tumors of the Glioma Group on a Histogenetic Basis with a Correlated Study of Prognosis. Lippincott: Philadelphia, PA, USA, 1926.
2. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
3. Kotliarova S, Fine HA. SnapShot: glioblastoma multiforme. Cancer Cell 2012; 21: 710-710, e1.
4. Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 2012; 26: 756-784.
5. Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 2010; 1802: 396-405.
6. Jirmanova L, Afanassieff M, Gobert-Gosse S, Markossian S, Savatier P. Differential contributions of ERK and PI3-kinase to the regulation of cyclin D1 expression and to the control of the G1/S transition in mouse embryonic stem cells. Oncogene 2002; 21: 5515-5528.
7. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-1812.
8. Guo JP, Coppola D, Cheng JQ. IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation. J Biol Chem 2011; 286: 37389-37398.
9. Ou YH, Torres M, Ram R, Formstecher E, Roland C, Cheng T et al. TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation. Mol Cell 2011; 41: 458-470.
10. Xie X, Zhang D, Zhao B, Lu MK, You M, Condorelli G et al. IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proc Natl Acad Sci USA 2011; 108: 6474-6479.
11. Chau TL, Gioia R, Gatot JS, Patrascu F, Carpentier I, Chapelle JP et al. Are the IKKs and IKK-related kinases TBK1 and IKK-epsilon similarly activated? Trends Biochem Sci 2008; 33: 171-180.
12. Verhelst K, Verstrepen L, Carpentier I, Beyaert R. IkappaB kinase epsilon (IKKepsilon): a therapeutic target in inflammation and cancer. Biochem Pharmacol 2013; 85: 873-880.
13. Shen RR, Hahn WC. Emerging roles for the non-canonical IKKs in cancer. Oncogene 2011; 30: 631-641.
14. Li H, Chen L, Zhang A, Wang G, Han L, Yu K et al. Silencing of IKKepsilon using siRNA inhibits proliferation and invasion of glioma cells in vitro and in vivo. Int J Oncol 2012; 41: 169-178.
15. Chien Y, Kim S, Bumeister R, Loo YM, Kwon SW, Johnson CL et al. RalB GTPasemediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell 2006; 127: 157-170.
16. Delhase M, Kim SY, Lee H, Naiki-Ito A, Chen Y, Ahn ER et al. TANK-binding kinase 1 (TBK1) controls cell survival through PAI-2/serpinB2 and transglutaminase 2. Proc Natl Acad Sci USA 2012; 109: E177-E186.
17. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009; 462: 108-112.
18. Goncalves A, Burckstummer T, Dixit E, Scheicher R, Gó rna MW, Karayel E et al. Functional dissection of the TBK1 molecular network. PLoS One 2011; 6: e23971.
19. Rudashevskaya EL, Sacco R, Kratochwill K, Huber ML, Gstaiger M, Superti-Furga G et al. A method to resolve the composition of heterogeneous affinity-purified protein complexes assembled around a common protein by chemical crosslinking, gel electrophoresis and mass spectrometry. Nat Protoc 2013; 8: 75-97.
20. Larabi A, Devos JM, Ng SL, Nanao MH, Round A, Maniatis T et al. Crystal structure and mechanism of activation of TANK-binding kinase 1. Cell Rep 2013; 3: 734-746.
21. Tu D, Zhu Z, Zhou AY, Yun CH, Lee KE, Toms AV et al. Structure and ubiquitination-dependent activation of TANK-binding kinase 1. Cell Rep 2013; 3: 747-758.
22. Shaw AS, Filbert EL. Scaffold proteins and immune-cell signalling. Nat Rev Immunol 2009; 9: 47-56.
23. Clark K, Takeuchi O, Akira S, Cohen P. The TRAF-associated protein TANK facilitates cross-talk within the IkappaB kinase family during Toll-like receptor signaling. Proc Natl Acad Sci USA 2011; 108: 17093-17098.
24. Chariot A, Leonardi A, Muller J, Bonif M, Brown K, Siebenlist U. Association of the adaptor TANK with the I kappa B kinase (IKK) regulator NEMO connects IKK complexes with IKK epsilon and TBK1 kinases. J Biol Chem 2002; 277: 37029-37036.
25. Kawagoe T, Takeuchi O, Takabatake Y, Kato H, Isaka Y, Tsujimura T et al. TANK is a negative regulator of Toll-like receptor signaling and is critical for the prevention of autoimmune nephritis. Nat Immunol 2009; 10: 965-972.
26. Renner F, Saul VV, Pagenstecher A, Wittwer T, Schmitz ML. Inducible SUMO modification of TANK alleviates its repression of TLR7 signalling. EMBO Rep 2011; 12: 129-135.
27. Guan H, Zhang H, Cai J, Wu J, Yuan J, Li J et al. IKBKE is over-expressed in glioma and contributes to resistance of glioma cells to apoptosis via activating NF-kappaB. J Pathol 2011; 223: 436-445.
28. Wang H, Zhang W, Huang HJ, Liao WS, Fuller GN. Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest 2004; 84: 941-951.
29. Golding SE, Rosenberg E, Valerie N, Hussaini I, Frigerio M, Cockcroft XF et al. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther 2009; 8: 2894-2902.
30. Xu TR, Vyshemirsky V, Gormand A et al. Inferring signaling pathway topologies from multiple perturbation measurements of specific biochemical species. Sci Signal 2010; 3: ra20.
31. Fey D, Croucher DR, Kolch W, Kholodenko BN. Crosstalk and signaling switches in mitogen-activated protein kinase cascades. Front Physiol 2012; 3: 355.
32. Shim JH, Xiao C, Paschal AE, Bailey ST, Rao P, Hayden MS et al. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev 2005; 19: 2668-2681.
33. Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov 2013; 3: 742-750.
34. Poulikakos PI, Solit DB. Resistance to MEK inhibitors: should we co-target upstream? Sci Signal 2011; 4: pe16.
35. Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells. J Pharmacol Exp Ther 2009; 329: 1063-1070.
36. Tarassishin L, Lee SC. Interferon regulatory factor 3 alters glioma inflammatory and invasive properties. J Neurooncol 2013; 113: 185-194.
37. Dhanasekaran DN, Kashef K, Lee CM, Xu H, Reddy EP. Scaffold proteins of MAPkinase modules. Oncogene 2007; 26: 3185-3202.
38. Weigle B, Ebner R, Temme A, Schwind S, Schmitz M, Kiessling A et al. Highly specific overexpression of the transcription factor SOX11 in human malignant gliomas. Oncol Rep 2005; 13: 139-144.
39. Dahan N, Choder M. The eukaryotic transcriptional machinery regulates mRNA translation and decay in the cytoplasm. Biochim Biophys Acta 2013; 1829: 169-173.
40. Hao S, Baltimore D. The stability of mRNA influences the temporal order of the induction of genes encoding inflammatory molecules. Nat Immunol 2009; 10: 281-288.
41. Rogatto SR, Casartelli C. A specific recurrent chromosomal breal region (2q24-2q32) in human gliomas. Re Brazil Genet 1988; 11: 475-479.
42. Crespo I, Tao H, Nieto AB, Rebelo O, Domingues P, Vital AL et al. Amplified and homozygously deleted genes in glioblastoma: impact on gene expression levels. PLoS One 2012; 7: e46088.
43. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009; 8: 3274-3284.
44. Endo K, Takeshita T, Kasai H, Sasaki Y, Tanaka N, Asao H et al. STAM2, a new member of the STAM family, binding to the Janus kinases. FEBS Lett 2000; 477: 55-61.
45. Zhu VF, Yang J, Lebrun DG, Li M. Understanding the role of cytokines in Glioblastoma Multiforme pathogenesis. Cancer Lett 2012; 316: 139-150.
46. Zhao W. Negative regulation of TBK1-mediated antiviral immunity. FEBS Lett 2013; 587: 542-548.
47. Yang CH, Murti A, Pfeffer LM. STAT3 complements defects in an interferonresistant cell line: evidence for an essential role for STAT3 in interferon signaling and biological activities. Proc Natl Acad Sci USA 1998; 95: 5568-5572.
48. Guryanova OA, Wu Q, Cheng L, Lathia JD, Huang Z, Yang J et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell 2011; 19: 498-511.
49. Najbauer J, Huszthy PC, Barish ME, Garcia E, Metz MZ, Myers SM et al. Cellular host responses to gliomas. PLoS One 2012; 7: e35150.
50. Yeung YT, Bryce NS, Adams S, Braidy N, Konayagi M, McDonald KL et al. p38 MAPK inhibitors attenuate pro-inflammatory cytokine production and the invasiveness of human U251 glioblastoma cells. J Neurooncol 2012; 109: 35-44.
51. Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW, Vandenberg S et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 2010; 24: 1731-1745.
52. Berindan-Neagoe I, Chiorean R, Braicu C et al. Quantitative mRNA expression of genes involved in angiogenesis, coagulation and inflammation in multiforme glioblastoma tumoral tissue versus peritumoral brain tissue: lack of correlation with clinical data. Eur Cytokine Netw 2012; 23: 45-55.
53. Weller M, Fontana A. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-cell apoptosis, and the immune privilege of the brain. Brain Res Brain Res Rev 1995; 21: 128-151.
54. Dix AR, Brooks WH, Roszman TL, Morford LA. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 1999; 100: 216-232.
55. Moreno R, Sobotzik JM, Schultz C, Schmitz ML. Specification of the NF-kappaB transcriptional response by p65 phosphorylation and TNF-induced nuclear translocation of IKK epsilon. Nucleic Acids Res 2010; 38: 6029-6044.